prostate cancer

The United States Preventive Services Task Force released a statement that prostate-specific antigen-based screening for prostate cancer should be avoided in men aged 70 years and older.
A recent study compared the costs and toxicities of proton radiation, stereotactic body radiotherapy, and intensity-modulated radiotherapy for younger patients with prostate cancer.
The National Comprehensive Cancer Network issued updated guidelines for prostate cancer, including new information about the role of family history, specific mutations, and microsatellite instability testing.
The FDA has approved the first treatment for a type of localized prostate cancer, using a novel endpoint to support the approval.
Researchers presenting at the 2018 ASCO Genitourinary Cancers Symposium compared the costs associated with two different approaches to management of low-risk prostate cancer and gave a recommendation toward a value-based care model.
The FDA has approved a hormone-based chemotherapy in combination with prednisone for metastatic high-risk castration-sensitive prostate cancer.
A cost-effectiveness analysis presented at the 2018 Genitourinary Cancers Symposium examined the use of a hydrogel rectal spacer in patients with prostate cancer undergoing intensity-modulated radiation therapy.
The addition of docetaxel to first-line long-term hormone therapy in prostate cancer improves overall health-related quality of life, reduces the need for further therapy, and is cost effective.
A study to be presented at the 2018 ASCO Genitourinary Cancers Symposium applied the ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale to assess the value of abiraterone acetate and enzalutamide in advanced prostate cancer.
A clinical pathway for patients with prostate cancer patients improved the implementation of evidence-based strategies for the management of androgen deprivation therapy-induced side effects.